Inicio › Enfermedades autoinmunes › Massachusetts › Boston
Ensayos clínicos de Enfermedades autoinmunes en Boston, MA
13 estudios para Enfermedades autoinmunes buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
ReclutandoFase 2/3
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
ReclutandoFase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
ReclutandoFase 3
- Boston Children's Cancer Center, Boston
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
ReclutandoFase 3
- Tufts Medical Center, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
ReclutandoFase 3
- Massachusetts General Hospital, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
ReclutandoFase 3
- Massachusetts General Hospital, Boston
Testimonials and Navigation in Rheumatology
Reclutando
- Brigham Women's Hospital, Boston
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
ReclutandoFase 1/2
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
ReclutandoFase 1/2
- Brigham and Women's Hospital, Boston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
ReclutandoFase 1/2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital - Accepting Young Adult and Adolescent Patients, Boston
- y 1 más
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
ReclutandoFase 1
- Brigham And Womens Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
ReclutandoFase 1
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
Más información sobre Enfermedades autoinmunes en MedlinePlus
Ensayos de Enfermedades autoinmunes en otras ciudades
- Houston, TX21 estudios
- Washington, DC19 estudios
- New York City, NY19 estudios
- Philadelphia, PA17 estudios
- Durham, NC15 estudios
- Chicago, IL13 estudios
- Los Angeles, CA12 estudios
- Atlanta, GA9 estudios
- Dallas, TX9 estudios
- Miami, FL8 estudios
- Milwaukee, WI8 estudios
- Cleveland, OH8 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer (todos los tipos)90 estudios
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer de pulmón63 estudios
- Cáncer del colon y del recto62 estudios
- Cáncer de ovario62 estudios
- Cáncer metastásico61 estudios
- Cáncer de próstata56 estudios
- Cáncer de endometrio51 estudios
- Depresión50 estudios
- Fallo cardíaco46 estudios
- Mieloma múltiple45 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.